A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Rechazo al injerto; Rechazo a un órgano o tejido
La hemoclasificación ABO y la tipificación de HLA (antígeno tisular) antes de un trasplante ayudan a garantizar una compatibilidad cercana. Usted generalmente necesitará tomar el medicamento para inhibir el sistema inmunitario por el resto de su vida para evitar el rechazo del tejido.
El hecho de tener cuidado al tomar adecuadamente los medicamentos después del trasplante y de tener una vigilancia atenta por parte del médico puede ayudar a prevenir el rechazo.
Eghtesad B, Miller CM, Fung JJ. Liver transplantation management. In: Carey WD, ed. Cleveland Clinic: Current Clinical Medicine. 2nd ed. Philadelphia, Pa: Saunders Elsevier; 2010.
Barry JM, Jordan ML, Conlin MJ. Renal transplantation. In: Wein AJ, ed. Campbell-Walsh Urology. 9th ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 40.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885